Display options
Cite
Paulsen K, Tauber S, Timm J, et al. The cannabinoid receptors agonist WIN55212-2 inhibits macrophageal differentiation and alters expression and phosphorylation of cell cycle control proteins. Cell Commun Signal. 2011;9:33doi: 10.1186/1478-811X-9-33.
Paulsen, K., Tauber, S., Timm, J., Goelz, N., Dumrese, C., Stolzing, A., Hass, R., & Ullrich, O. (2011). The cannabinoid receptors agonist WIN55212-2 inhibits macrophageal differentiation and alters expression and phosphorylation of cell cycle control proteins. Cell communication and signaling : CCS, 933. https://doi.org/10.1186/1478-811X-9-33
Paulsen, Katrin, et al. "The cannabinoid receptors agonist WIN55212-2 inhibits macrophageal differentiation and alters expression and phosphorylation of cell cycle control proteins." Cell communication and signaling : CCS vol. 9 (2011): 33. doi: https://doi.org/10.1186/1478-811X-9-33
Paulsen K, Tauber S, Timm J, Goelz N, Dumrese C, Stolzing A, Hass R, Ullrich O. The cannabinoid receptors agonist WIN55212-2 inhibits macrophageal differentiation and alters expression and phosphorylation of cell cycle control proteins. Cell Commun Signal. 2011 Dec 28;9:33. doi: 10.1186/1478-811X-9-33. PMID: 22204398; PMCID: PMC3273436.
Copy Download .nbib Format: NLM
Share it on

Cell Commun Signal. 2011 Dec 28;9:33. doi: 10.1186/1478-811X-9-33.

The cannabinoid receptors agonist WIN55212-2 inhibits macrophageal differentiation and alters expression and phosphorylation of cell cycle control proteins.

Cell communication and signaling : CCS

Katrin Paulsen, Svantje Tauber, Johanna Timm, Nadine Goelz, Claudia Dumrese, Alexandra Stolzing, Ralf Hass, Oliver Ullrich

Affiliations

  1. Division of Cellbiology, Institute of Anatomy, Faculty of Medicine, University of Zurich, Switzerland. [email protected].

PMID: 22204398 PMCID: PMC3273436 DOI: 10.1186/1478-811X-9-33

Abstract

In this study we investigated if and how cannabinoid receptor stimulation regulates macrophageal differentiation, which is one of the key steps in the immune effector reaction. For that reason, we used a well established differentiation model system of human U937 myelocytic leukemia cells that differentiate along the monocyte/macrophage lineage upon stimulation with the phorbol ester PMA. Constant cannabinoid receptor (CB) stimulation was performed using WIN55212-2, a potent synthetic CB agonist. We found that WIN55212-2 inhibited CB1/2-receptor-dependent PMA-induced differentiation of human myelocytic U937 cells into the macrophageal phenotype, which was associated with impaired vimentin, ICAM-1 and CD11b expression. In the presence of WIN55212-2, cdc2 protein and mRNA expression was progressively enhanced and Tyr-15-phosporylation of cdc2 was reduced in differentiating U937 cells. Additionally, p21Waf1/Cip1 expression was up-regulated. PMA-induced apoptosis was not enhanced by WIN55212-2 and differentiation-associated c-jun expression was not altered. In conclusion, we suppose that WIN55212-2-induced signals interferes with cell-cycle-arrest-signaling in differentiating myelocytic cells and thus inhibits macrophageal differentiation. Thus, it is possible that the cannabinoid system is able to influence one of the key steps in the immune effector function, the monocytic-macrophageal differentiation by alteration of cell cycle control proteins cdc2 and p21, and is therefore representing a promising option for therapeutic intervention in exacerbated immune reactions.

References

  1. Oncogene. 1999 Nov 1;18(45):6158-62 - PubMed
  2. Int J Immunopharmacol. 1993 Apr;15(3):371-82 - PubMed
  3. J Immunol. 1998 Aug 1;161(3):1390-8 - PubMed
  4. Eur J Biochem. 1995 Aug 15;232(1):54-61 - PubMed
  5. J Neurosci. 2003 May 15;23(10):4127-33 - PubMed
  6. Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):25-34 - PubMed
  7. Curr Pharm Des. 2008;14(23):2266-78 - PubMed
  8. FEBS Lett. 1988 Aug 29;236(2):396-400 - PubMed
  9. J Biol Chem. 1999 Oct 1;274(40):28286-92 - PubMed
  10. Cancer Res. 1992 Mar 15;52(6):1445-50 - PubMed
  11. Cell. 1995 Jan 27;80(2):225-36 - PubMed
  12. Br J Pharmacol. 2003 Jun;139(4):775-86 - PubMed
  13. Differentiation. 1998 May;63(1):33-42 - PubMed
  14. EMBO J. 1991 Nov;10(11):3321-9 - PubMed
  15. J Biol Chem. 2006 Dec 22;281(51):39480-91 - PubMed
  16. PLoS One. 2010 Jan 14;5(1):e8688 - PubMed
  17. FEBS Lett. 2004 Nov 19;577(3):563-9 - PubMed
  18. Br J Pharmacol. 2007 Dec;152(7):1092-101 - PubMed
  19. Nature. 1989 Nov 2;342(6245):39-45 - PubMed
  20. Int J Immunopharmacol. 1996 Dec;18(12):749-52 - PubMed
  21. J Neurosci. 1997 Jul 15;17(14):5327-33 - PubMed
  22. Nature. 1993 Sep 2;365(6441):61-5 - PubMed
  23. Cell Growth Differ. 1991 Nov;2(11):541-8 - PubMed
  24. J Cell Biochem. 2011 Apr;112(4):1192-205 - PubMed
  25. Nature. 1980 Jan 17;283(5744):249-256 - PubMed
  26. Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):201-10 - PubMed
  27. J Leukoc Biol. 1985 Apr;37(4):407-22 - PubMed
  28. Br J Pharmacol. 2007 Nov;152(5):825-31 - PubMed
  29. Nat Cell Biol. 2002 May;4(5):E131-6 - PubMed
  30. Cell. 1986 Apr 11;45(1):145-53 - PubMed
  31. Chem Phys Lipids. 2000 Nov;108(1-2):221-9 - PubMed
  32. Blood. 1997 Nov 1;90(9):3430-7 - PubMed
  33. Biochem Pharmacol. 2004 Apr 1;67(7):1381-7 - PubMed
  34. Cell Cycle. 2004 Feb;3(2):111-3 - PubMed
  35. Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):353-61 - PubMed
  36. Eur J Biochem. 1993 May 15;214(1):173-80 - PubMed
  37. FEBS Lett. 1995 Aug 7;369(2-3):177-82 - PubMed
  38. Biochem Pharmacol. 1996 Sep 13;52(5):743-51 - PubMed
  39. J Cell Physiol. 1991 Oct;149(1):125-31 - PubMed
  40. J Neuroimmunol. 1998 Mar 15;83(1-2):116-23 - PubMed
  41. Eur J Cell Biol. 1990 Apr;51(2):265-71 - PubMed
  42. Eur J Pharmacol. 2001 Jul 6;423(2-3):203-10 - PubMed
  43. Mol Biol Cell. 1994 Sep;5(9):989-1001 - PubMed
  44. Biochem Biophys Res Commun. 2001 Jan 12;280(1):244-8 - PubMed
  45. Mol Pharmacol. 1988 Mar;33(3):297-302 - PubMed
  46. J Pharmacol Exp Ther. 2000 Apr;293(1):136-50 - PubMed
  47. Nature. 1990 Aug 9;346(6284):561-4 - PubMed

Publication Types